ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Warma should resign

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Aug 07, 2024 1:44pm

150 Views

Post# 36167864

Warma should resign

This CEO and the BOD are so useless and have no financial sense whatsoever. It's amazing how totally inept people get these positions. Going to NASDAQ was a huge mistake and the massive constant dilution even a bigger mistake. Look at the salaries they get!!!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China